华东医药引入Biomee 系列，正是看中了其背后庞大且持续增长的市场。皮肤学级护肤品介于药品与普 通化妆品之间，属于功能性护肤范畴。近年来，随着消费者科学护肤意识的提升，市场发展迅速。 在"成分党"与"功效护肤"趋势推动下，具备医学背景、配方精简、针对性强的产品受到消费者青睐。据 普华有策调研数据显示，2017年，中国皮肤学级护肤品市场规模为85.2亿元，并以24.1%的年均复合增 长率增至2023年的311.7亿元。预计2028年增长至650亿元。Biomee 系列所针对的皮肤干燥与屏障受损 问题，是覆盖各年龄层的普遍痛点，市场基础广阔。 此外，此次Ⅲ期临床试验完成首例受试者入组的MC2-01乳膏是中美华东与MC2于2023年8月签署合作协 议引进的创新皮肤外用制剂产品，中美华东拥有该产品在大中华区（含中国大陆，香港、澳门和台湾地 区）的独家许可，包括临床开发、注册及商业化权益。MC2-01是一种卡泊三醇和倍他米松的固定剂量 复方制剂，用于局部治疗成人斑块状银屑病，包括头皮银屑病，利用MC2独有的药物递送系统PAD 技 术，使其成为一种方便使用的水性乳膏。 1月5日，华东医药（000963）股份有限公司（S ...

Core Insights - The pharmaceutical industry is witnessing significant strategic collaborations, with companies like Kangzheng Pharmaceutical partnering with global giants like Novartis to enhance their market presence in specialized fields such as ophthalmology and dermatology [1] Group 1: Kangzheng Pharmaceutical's Strategic Moves - Kangzheng Pharmaceutical has signed a distribution agreement with Novartis, gaining exclusive rights for two ophthalmic drugs in mainland China, indicating a strong commitment to the ophthalmology sector [1] - The company is also focusing on its dermatology segment through the spin-off of its skin health business, Dermy Pharmaceuticals, which has submitted a listing application to the Hong Kong Stock Exchange [1] Group 2: Market Potential in Dermatology - The white spot disease (vitiligo) market is highlighted as a significant opportunity, with the treatment market projected to grow from 2.8 billion RMB in 2024 to approximately 21.9 billion RMB by 2035, reflecting a compound annual growth rate (CAGR) of 20.7% [2] - Dermy Pharmaceuticals is advancing its lead product, Ruxolitinib cream, which is the first and only FDA and EMA-approved topical JAK inhibitor for vitiligo, currently in the new drug application approval stage in China [3] Group 3: Other Dermatological Conditions - Psoriasis, affecting around 7.2 million patients in China, is seeing a shift towards biologics and small molecule drugs as preferred treatment options, with Dermy Pharmaceuticals' Tildrakizumab injection positioned as a second approved IL-23 monoclonal antibody in the market [4] - Atopic dermatitis, impacting over 54 million people in China, is expected to see its treatment market grow from 12.1 billion RMB in 2024 to 39.4 billion RMB by 2035, with Dermy Pharmaceuticals pursuing multiple pipeline strategies to address this demand [6][7] Group 4: Acne Treatment Innovations - Acne is a prevalent skin issue, with a reported prevalence of 8.1% in the Chinese population, leading to a growing market for effective skincare solutions [8] - Dermy Pharmaceuticals is leveraging its brand advantage with the launch of the Xiliao Duo series, targeting acne treatment and prevention, while also offering soothing products for atopic dermatitis and sensitive skin [8]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securiti ...

Core Viewpoint - The article highlights the widespread issue of acne among adolescents in China, emphasizing the psychological and social impacts it has on individuals, and the need for timely and effective treatment rather than the common misconception that it is a normal part of growing up [19][21]. Group 1: Prevalence and Impact of Acne - A study indicates that 95% of individuals experience some degree of acne, with 3% to 7% of patients developing scars [1]. - Many adolescents face self-esteem issues and social anxiety due to acne, which can affect their personal and professional lives [1][19]. Group 2: Treatment Challenges - Parents often resort to ineffective home remedies or delay seeking professional help, believing that acne will resolve on its own [19][21]. - The article discusses various treatment experiences, including the use of topical medications and oral antibiotics, which often come with side effects and limited effectiveness [20]. Group 3: Psychological Effects - Acne can lead to significant emotional distress, with many individuals feeling self-conscious and avoiding social interactions [19][21]. - The stigma associated with acne can exacerbate feelings of isolation and anxiety among affected adolescents [19]. Group 4: Need for Awareness and Education - There is a lack of understanding about acne among the general population, with 60.4% of people not fully aware of the condition [19]. - The article calls for increased awareness and education for both parents and adolescents regarding the importance of early intervention and proper treatment [21]. Group 5: Advances in Treatment - Recent guidelines and advancements in acne treatment are being introduced, aiming to provide safer and more effective options for patients [20]. - The introduction of new technologies and treatment methods is seen as a positive step towards addressing the acne epidemic among youth [20].

Company Overview - 德镁医药 is an innovative pharmaceutical company focused on skin health, operating under 康哲药业. It specializes in prescription drugs and dermatological skincare products, with three products already on the market and several candidates in various clinical stages [1] Financial Performance - Revenue for 2023 reached RMB 472.56 million, a year-on-year increase of 23.2%, driven by a robust growth in prescription drugs and a significant surge in skincare products [2][3] - Prescription drug revenue was RMB 424.82 million in 2023, up 13.6% from RMB 374.04 million in 2022, accounting for 89.9% of total revenue [2] - Skincare product revenue skyrocketed by 404.4% to RMB 47.74 million in 2023, primarily due to successful e-commerce promotions [3] Profitability and Margins - The overall gross margin improved to 76.9% in 2023, up 6.8 percentage points from the previous year, with a significant reduction in net loss to RMB 5 million [5] - The gross margin for prescription drugs was 76.6%, while skincare products achieved a gross margin of 79.0% [5] - However, the gross margin is expected to decline to 63.5% in 2024 due to increased costs and pricing pressures from insurance adjustments [7][8] Debt Structure and Cash Levels - A debt-to-equity conversion in 2024 significantly improved the company's balance sheet, reducing liabilities from RMB 15.75 billion to RMB 1.54 billion [10] - Despite the reduction in debt, cash reserves remain tight, with only RMB 2.82 billion available at the end of 2024 [10] Competitive Advantages - 德镁医药 has the broadest coverage of skin disease indications in China, with nine conditions addressed, surpassing competitors [11] - Key products like 益路取 for psoriasis and 喜辽妥 for scar treatment have unique advantages, including insurance coverage and lack of direct competition [12][14] - The company benefits from a strong distribution network, leveraging 康哲药业's existing relationships with over 10,000 hospitals and 100,000 pharmacies [13] Industry Context - The Chinese skin treatment and care market was valued at RMB 76.4 billion in 2023, with a projected CAGR of 10.6% through 2035, driven by the high prevalence of chronic skin diseases [20] - The demand for dermatological skincare products is also increasing, with significant growth in e-commerce channels [20]

Core Insights - The article emphasizes the importance of diet in maintaining skin health, highlighting that collagen is crucial for skin elasticity and smoothness. As people age, their natural collagen production declines due to various factors, including stress and poor diet [1] Food Sources of Collagen - Bone broth is rich in collagen, gelatin, and essential amino acids, promoting collagen production and skin health [2] - Fatty fish like salmon and tuna are excellent sources of omega-3 fatty acids and marine collagen, which enhance skin elasticity and hydration [3] - Eggs, while not containing collagen directly, are rich in proline and lysine, amino acids vital for collagen synthesis [4] - Citrus fruits are high in vitamin C, essential for stabilizing and generating collagen molecules [5] - Berries contain antioxidants and vitamin C, which are important for collagen production and skin protection [6] - Leafy greens are nutrient-dense and support collagen synthesis while protecting the skin from damage [7] - Nuts and seeds provide omega-3 fatty acids and zinc, crucial for collagen production and skin repair [8] - Garlic contains sulfur, which is necessary for collagen production and helps rebuild damaged collagen fibers [9] - Tomatoes are rich in lycopene, an antioxidant that protects the skin from UV damage and supports collagen synthesis [10] - Avocados provide healthy fats and vitamins E and C, essential for collagen production and skin health [11] - Soy products are excellent sources of plant protein and isoflavones, supporting collagen production and improving skin elasticity [12] - Kiwi has a high vitamin C content, aiding in collagen formation and providing antioxidants for skin health [13] - Pumpkin seeds are rich in beta-carotene, vitamin C, and zinc, all important for collagen synthesis and skin repair [14] - Cashews are high in copper, which is vital for collagen connection and maintaining skin elasticity [15] - Colorful bell peppers are rich in vitamin C and antioxidants, helping to reduce inflammation and protect the skin [16] - Mushrooms, especially sun-exposed varieties, are a rare plant source of vitamin D, crucial for collagen integrity [17]

Core Viewpoint - The increasing prevalence of skin health issues among the elderly in China is evolving from a cosmetic concern to a significant public health crisis, particularly highlighted by the rising incidence of shingles [1][2]. Group 1: Skin Health Challenges - There are over 2,000 named skin diseases, making dermatology one of the most complex medical fields [2]. - The incidence of skin diseases in China is alarmingly high, with a prevalence rate of 40%-70%, leading to significant health-related quality of life losses [2]. - Shingles, a disease that significantly increases in incidence with age, affects about one-third of individuals in their lifetime, with approximately 600,000 new cases annually in China, of which 1.56 million are in individuals over 50 [2]. Group 2: Chronic Diseases and Shingles - Patients with chronic diseases such as diabetes and cardiovascular conditions have a 26%-41% higher risk of developing shingles compared to the general population [2][3]. - The presence of shingles can exacerbate existing chronic conditions and increase the risk of severe pain, leading to a higher likelihood of depression and anxiety among affected individuals [3]. Group 3: Awareness and Prevention - There is a significant gap in awareness and preventive measures regarding shingles among the elderly, with over 60% believing they are not at risk [4]. - A study indicates that 30% of patients delay treatment due to the misconception that they can endure the pain [4]. - Effective public health education is essential to shift the mindset from "enduring pain" to "proactive prevention," emphasizing the importance of vaccination and early intervention [4][5]. Group 4: Community Health Initiatives - Community health service centers are crucial in addressing these health trends, particularly in managing chronic diseases and their complications [3][5]. - New models of integrated medical and preventive care are being explored, such as the introduction of public health physician prescriptions to enhance preventive measures [5]. - Trust in healthcare providers, particularly family doctors, is vital for encouraging residents to engage in preventive health actions, including vaccinations [5].

Core Viewpoint - 康哲药业 plans to spin off its skin health subsidiary, 德镁医药, and list it on the Hong Kong main board through a distribution of shares to existing shareholders, without diluting their equity [1] Group 1: Company Overview - 德镁医药 focuses on skin health and is responsible for 康哲药业's domestic skin health business, providing comprehensive solutions from prevention to long-term care [1] - The company has incurred losses during the performance record period due to ongoing investments in business development, which aligns with the growth logic of a developing enterprise [1] Group 2: Product Pipeline and Market Position - 德镁医药's product pipeline includes three marketed products, four candidates in clinical or late-stage trials, and two preclinical candidates, covering major skin diseases such as psoriasis, vitiligo, and atopic dermatitis [2] - The company ranks first among Chinese innovative pharmaceutical companies in terms of the number of skin disease indications covered by products in late-stage clinical trials or commercialization [2] - Notable products include the innovative drug, 芦可替尼乳膏, which targets the unapproved treatment area of vitiligo, and the commercialized drug IL-23益路取, which is penetrating the psoriasis market [1][2]

Core Viewpoint - The article discusses the emergence of Demy Pharmaceutical, a subsidiary of Kangzhe Pharmaceutical, focusing on the development and market potential of the drug "Ruxolitinib Cream" for treating vitiligo, amidst a growing demand for effective skin health products in China [1][2]. Company Overview - Demy Pharmaceutical is set to independently list in Hong Kong, having submitted its prospectus in April 2023, and is positioned to capitalize on the skin health market, which is projected to be worth billions [1][2]. - The company has a strong product pipeline, including Ruxolitinib Cream, which is the only FDA-approved JAK inhibitor for vitiligo, and other skin-related products [3][5]. Market Potential - There are over 10 million vitiligo patients in China, and the market for effective treatments is largely untapped, with Ruxolitinib Cream expected to generate significant revenue, projected at $340 million in its first full sales year [4][10]. - The skin health market is characterized by a high demand for unique and effective treatments, with Demy focusing on products that have a strong market need and limited competition [7][11]. Financial Performance - Demy Pharmaceutical has shown promising financials, with revenues expected to exceed 600 million yuan in 2024, reflecting a growth trend in the skin health segment [2][7]. - The company has maintained a positive cash flow despite not yet being profitable, indicating strong market interest and potential for future growth [2][10]. Product Pipeline - The product pipeline includes several other skin prescription drugs, with a focus on unique and differentiated products that address significant medical needs [5][7]. - The company has successfully introduced products that are the only approved treatments for specific conditions in China, enhancing its competitive edge [7][11]. Sales Strategy - Demy Pharmaceutical's sales strategy emphasizes leveraging its parent company's marketing expertise and established distribution channels, with a focus on hospital and retail pharmacy coverage [10][12]. - The company has a strong commercial team, with over 85% of its workforce dedicated to sales, which is crucial for its growth in the competitive biopharmaceutical market [10][12].